Array BioPharma has entered into a strategic clinical research collaboration with Bristol-Myers Squibb (BMS) to evaluate the combination of binimetinib with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in a Phase I/II clinical trial to treat metastatic colorectal cancer.

Binimetinib is Array’s investigational inhibitor of MEK, which is a protein kinase in the MAPK signalling pathway that reportedly modulates various cellular activities such as proliferation, differentiation, survival and angiogenesis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Opdivo is an immune checkpoint inhibitor of programmed death-1 (PD-1), while Yervoy is a recombinant, human monoclonal antibody developed to block the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4).

The Phase I/II trial is designed to determine recommended dose regimens for further evaluation.

Array BioPharma chief executive officer Ron Squarer said: "Based on emerging data, we believe that studying combinations of targeted therapies, such as binimetinib, with immuno-oncology agents, such as Opdivo and Yervoy, could provide important scientific advances for patients fighting cancer."

"Colorectal cancer remains a challenging tumour where immunotherapy benefits have been limited to a subset of patients."

The trial will also assess the preliminary anti-tumour activity of binimetinib with Opdivo combination and binimetinib combined with Opdivo + Yervoy in patients with microsatellite stable tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bristol-Myers Squibb senior vice-president and Oncology Development head Fouad Namouni said: "Colorectal cancer remains a challenging tumour where immunotherapy benefits have been limited to a subset of patients.

"We are committed to investigating a wide range of oncology therapies, and look forward to studying the combination of Array's MEK inhibitor and our immunotherapies with the goal of developing more treatment options for patients."

Expected to start in the second half of this year, the trial’s findings will be used for further clinical development of the combination therapies.

Binimetinib is also being evaluated in the Phase III COLUMBUS trial for BRAF-mutant melanoma and the Phase III BEACON CRC trial to treat BRAF V600E-mutant colorectal cancer patients.